PURPOSE: Poor ocular surface health in dry eye (DE) can impact postsurgical outcomes. Blink Triple Care (BTC) drops combine a lubricant (polyethylene glycol 400) with a natural-oil nano-emulsion and hyaluronic acid in a preservative-free formulation to promote ocular surface homeostasis. This study evaluated outcomes and satisfaction with BTC in DE.

METHODS: In this prospective, cross-sectional survey study in the US, adult self-identified DE sufferers were recruited from a representative panel. Eligible participants had used over-the-counter artificial tears in the prior 6 months, with confirmed DE symptoms documented by ocular surface disease index (OSDI) scores. Exclusion criteria were use of prescription eye drops, ocular surgery within the past 6 months, or allergy to formulation ingredients. Participants received a masked bottle with 1–2 drops to be administered once in the morning. Surveys covering global symptoms, DE-specific symptoms, and satisfaction were completed immediately after and at 4, 8, and 10 hours (h) after instillation.

RESULTS: Among participants (N=622), baseline OSDI scores indicated mild, moderate, or moderate/severe DE in 32%, 34%, and 34% of participants, respectively. Immediately after use, 88% of participants reported that their eyes felt better. This level of agreement (sum of ‘agree’ and ‘strongly agree’) was maintained across all timepoints (4h, 92%; 8h, 90%; 10h, 91%). Similarly, agreement rates were high and durable across key DE attributes at immediate, 4-, 8-, and 10-h timepoints: “my eyes feel moisturized” (90%, 83%, 80%, and 79%, respectively) and “my eyes feel comfortable” (88%, 87%, 83%, and 84%, respectively). At 10h, 81% of participants agreed that BTC “provides long-lasting relief”.

CONCLUSION: These real-world findings highlight the durable relief provided by BTC, which combines a natural-oil nano-emulsion with hyaluronic acid to lubricate the ocular surface and protect against tear evaporation. Patient-reported high performance suggests BTC can provide relief from mild-to-moderate dry eye symptoms for up to 10 hours following instillation.

PURPOSE: Dry eye syndrome (DES) causes chronic discomfort and visual disturbance. Lutein/zeaxanthin, curcumin, and vitamin D3 (LCD) are anti-inflammatory ocular surface protectants that, when taken as an oral supplement, improve DES symptoms and reduce inflammation. This analysis compares LCD efficacy and safety from an Indian and a larger US study.

METHODS: These 2 double-blind, placebo-controlled, 8-week studies randomized patients 1:1 to receive either LCD or placebo (PBO) soft gels to be taken with breakfast. The Indian study was conducted at a single site compared with the multicenter US study. The primary efficacy outcomes were change in tear volume (Schirmer’s test) and symptom severity (Ocular Surface Disease Index [OSDI] score) on days 14, 28, and 56. Secondary endpoints included tear film breakup time (TBUT), tear osmolarity, symptom progression (standard patient evaluation of eye dryness [SPEED] score), ocular surface disease (corneal/conjunctival staining), and inflammation (tear film presence of MMP-9) at each timepoint.

RESULTS: In both studies (US: N=116; India: N=59), change from baseline in the LCD group was significantly improved vs PBO in tear volume (Schirmer’s test; days 28 and 56; P<0.05) and symptom severity osdi score days 14 28 and 56 p><0.05). the us study found no between-group differences in artificial tear at use but the indian study saw reduced at use with time in the lcd group. both studies however showed significant reductions in ocular inflammation tear film matrix metalloprotease-9 mmp-9 positivity at day 56 p><0.05).>

CONCLUSION: Both studies show that, vs PBO, 8 weeks of daily LCD improves factors key to positive ocular surgery outcomes: tear volume and dry eye symptoms. Additionally, LCD significantly reduced ocular inflammation at 8 weeks. In both daily eye care and pre- and postsurgical protocols, LCD may provide clinically meaningful benefits to dry eye sufferers.

PURPOSE: To evaluate the spectacle independence and frequency of photic phenomena following the implantation of an enhanced monofocal IOL with higher-order aspheric coefficients on the central part of the posterior surface.

METHODS: This retrospective chart review included 87 patients who underwent cataract surgery and implantation of an enhanced monofocal IOL (enVista Aspire, Bausch & Lomb, Inc). This enhanced monofocal IOL encompasses higher-order aspheric coefficients on the central part of the posterior surface to slightly extend the depth of focus. Outcome measures were subjective assessment of spectacle independence and incidence of visual symptoms using the patient-reported spectacle independence questionnaire (PRSIQ).

RESULTS: The proportion of patients who reported that they wore glasses or contacts 'none' or 'a little of the time' was 100% for distance and 96.6% for intermediate vision. The frequency of visual symptoms was low, with 8% of patients reporting glare, and 1.2% of the patients each reporting halos or starbursts to occur 'all' or 'most of the time'. Patient satisfaction was high, with ~99% of patients being able to function comfortably without glasses/contacts "all" or most of the time" for distance and intermediate vision.

CONCLUSION: Implantation of enVista Aspire IOL exhibited excellent spectacle independence at far and intermediate distances. The frequency of photic phenomenon was low. Ninety-nine percent of patients could function comfortably without glasses/contacts.

PURPOSE: To evaluate the visual acuity outcomes and defocus curve of an enhanced monofocal IOL implanted bilaterally in cataract patients.

METHODS: This ambispective, single-arm, multicenter study included 82 subjects who had undergone bilateral implantation of an enhanced monofocal IOL, enVista Aspire (EA). EA is an IOL with intermediate optimized optics that provides a continuous depth of focus from distance to intermediate. The IOL uses an optical modification of the posterior aspheric surface to create a small continuous increase in IOL power within the central 1.5 mm diameter to slightly extend the depth of focus. Outcome measures included monocular (first implanted eye) and binocular visual acuities at distance, intermediate, and near, and the binocular defocus curve at least 2 months after IOL implantation in the second eye.

RESULTS: Postoperatively, mean logMAR UDVA and CDVA in the first implanted eyes were 0.12 ± 0.14 and -0.01± 0.09, respectively. Mean postoperative MRSE was -0.38 ± 0.47 D. Mean monocular logMAR UIVA and UNVA were 0.21± 0.15 and 0.42 ± 0.17; 58.5% of eyes achieved UIVA 20/32 or better, and 34.1% of eyes achieved UNVA 20/40 or better. The mean binocular logMAR DCIVA and DCNVA were 0.21 ± 0.13 and 0.39 ± 0.14, respectively, with 65.9% of patients achieving DCIVA 20/32 or better, and 35.4% achieving DCNVA 20/40 or better. Defocus curve showed 20/32 or better visual acuity for a defocus range of ~ +1.00 D to -1.25 D.

CONCLUSION: The implantation of an enhanced monofocal IOL resulted in improved depth of focus, yielding good visual acuity outcomes for intermediate vision with nearly 2/3 rd of the subjects achieving distance corrected intermediate visual acuity of 20/32 or better, postoperatively.

PURPOSE: To assess the visual outcomes at distance, intermediate, and near following the implantation of a full visual range IOL in cataract surgery patients.

METHODS: This retrospective study included patients who had undergone bilateral implantation of a full visual range IOL (enVista Envy IOL, Bausch and Lomb). Outcome measures included assessment of monocular uncorrected visual acuities at distance, intermediate, and near at postoperative 3 weeks.

RESULTS: Postoperatively, the data of 16 eyes (8 patients) were available for analysis. The mean logMAR UDVA was 0.12±0.14 with 81.3% of eyes achieving UDVA of 20/30 or better postoperatively. The mean postoperative manifest refraction spherical equivalent (MRSE) was -0.30 ± 0.35 D, with 87.5% of eyes achieving MRSE within 0.50 D. The mean UNVA was 0.12±0.09 logMAR, with 71.4% of eyes achieving UNVA of 20/25 or better, postoperatively. The mean UIVA was 0.06±0.08 logMAR, with 85.7% of eyes achieving UIVA 20/25 or better.

CONCLUSION: enVista Envy full visual range IOL implanted in cataract patients showed good visual outcomes at distance, intermediate and near.

PURPOSE: The purpose of this case series is to evaluate visual acuity outcomes of full visual range intraocular lens (IOL) in mild glaucoma patients underwent cataract surgery and minimally invasive glaucoma surgery (MIGS).

METHODS: This retrospective case series included patients underwent cataract surgery and MIGS with a full visual range IOL (enVista Envy, EN, Bausch & Lomb) implantation. Clinical endpoints collected were uncorrected and corrected distance visual acuity (UDVA/CDVA), uncorrected intermediate visual acuity (UIVA), manifest refraction spherical equivalent (MRSE), as well as pre and post-operative IOP. Adverse events were also collected.

RESULTS: 18 eyes of 13 patients with glaucoma underwent combined Phaco with MIGS including BANG (13), istent (3) and GSL (2), and implantation of the FVR IOL. Average age was 71, with 92% Caucasians, including 10 females and three males. Average CCT was 550 microns, MD was -4.0dB, PSD 3.0, GC-IPL 73 microns and RNFL 83 microns. Patients were on average on 1.2 glaucoma meds pre-operatively with a mean IOP of 18.0 mmHg. At the post-op 1 month visit, average UDVA was 20/20, UIVA 20/25 and UNVA 20/40, with a MRSE of 0.12 and an IOP of 15.3 mmHg on 0.1 topical meds.

CONCLUSION: In carefully selected patients with well controlled mild glaucoma, the implantation of a FVR IOL at the time of combined cataract and MIGS surgery resulted in decreased IOP, as well as an excellent uncorrected distance visual acuity, as well as good functional uncorrected intermediate and near visual acuity.

PURPOSE: To evaluate the spectacle independence and frequency of visual symptoms following bilateral implantation of a full visual range (FVR) IOL.

METHODS: This retrospective chart review included 78 patients who underwent cataract surgery and implantation of an FVR IOL (enVista Envy, Bausch & Lomb). This IOL is designed to provide a continuous range of vision, enhancing both near and distance vision. Outcome measures were subjective assessment of spectacle independence and incidence of visual symptoms using the patient-reported spectacle independence (PRSIQ).

RESULTS: The percentage of patients who responded that they wore glasses or contacts 'none' or 'a little of the time' was 100% for distance and intermediate, and 92.9% for near vision. The proportion of patients who reported that they could function comfortably 'all or most of the time' without wearing glasses or contacts was 100% for distance, 96.4% for intermediate, and 89.2% for near vision. The proportion of patients who reported visual symptoms 'some', 'a little', or 'none of the time' was 89.3% for glare, 82.1% for halos, and 92.9% for starbursts.

CONCLUSION: The FVR IOL demonstrated excellent spectacle independence for distance, intermediate, and near vision. The minimal occurrence of visual disturbances contributed to good IOL performance and high levels of overall patient satisfaction.

PURPOSE: This retrospective case series aimed to document healthcare providers' (HCPs) real-world experience of using the enVista ENVY (EN) and enVista ENVY toric (ETN) full visual range intraocular lenses (IOLs). This interim sub-analysis reports visual acuity outcomes with EN, stratified by residual refractive error.

METHODS: This interim sub-analysis of a retrospective, multicenter, cross-sectional study includes case report forms (CRFs) from 14 HCPs from the USA (n=12) and Canada (n=2). HCPs provided on-label EN/ETN electronic medical record cases using a standardized CRF to document real-world clinical performance. Key outcome measures included monocular vision outcomes (uncorrected distance VA [UDVA], corrected distance VA [CDVA], uncorrected intermediate VA [UIVA], uncorrected near VA [UNVA]), manifest refraction spherical equivalent (MRSE) and residual cylinder. Outcomes were stratified by residual refractive error (sphere, cylinder, and MRSE) in 0.25 D groups. Patients were followed for ≥6 months.

RESULTS: Eyes implanted with the EN IOL and residual sphere of -0.5 D achieved ≤20/25 UDVA, UIVA and UNVA in 25%, 100% and 100%, respectively. With a residual sphere of -0.25 D, ≤20/25 UDVA, UIVA and UNVA was achieved in 57%, 100% and 71%, respectively, and with a residual sphere of 0.00 D ≤20/25 UDVA, UIVA and UNVA was achieved in 70%, 71% and 44%, respectively. Eyes with a residual sphere of ≥+0.25 D achieved ≤20/25 UDVA, UIVA and UNVA in more than 80%, more than 82%, and more than 76%, respectively.

CONCLUSION: In this retrospective case series, the EN IOL provided good distance, intermediate, and near visual acuity for the majority of patients. Plano to hyperopic outcomes may lead to the best UDVA.

PURPOSE: To present a case series evaluating real-world clinical performance of the enVista ENVY (EN) and enVista ENVY toric (ETN) full visual range intraocular lenses (IOLs) in patients (pts) undergoing cataract surgery.

METHODS: This case series included 71 eyes implanted with the ETN or EN IOL by a single surgeon in the US between November 6, 2024, and July 30, 2025. Key outcomes measures included monocular and binocular vision outcomes (corrected distance visual acuity [CDVA], uncorrected distance visual acuity [UDVA], uncorrected intermediate visual acuity [UIVA], uncorrected near visual acuity [UNVA]), mean refractive spherical equivalent (MRSE), and occurrence of glistenings, posterior capsule opacification (PCO), and adverse events (AEs).

RESULTS: The analysis included 49 patients (28 EN, 43 ETN eyes). Mean±SD target SE was 0.23±0.16 (EN, n=27) and -0.19+0.13 (ETN, n=43). Monocular CDVA ≤20/25 was achieved in 100% (EN) and 95% (ETN); UDVA ≤20/32 in 86% and 77%; UIVA ≤20/25 in 95% and 84%; and UNVA ≤ J2 in 79% and 76%, respectively. Binocular CDVA ≤20/25 was achieved in 100% (EN) and 92% (ETN). Mean+SD MRSE and residual cylinder were -0.06±0.40 and -0.36±0.28 (EN), and -0.32±0.32 and -0.40±0.35 (ETN). No serious AEs or glistenings were observed.

CONCLUSION: In this real-world patient population, EN and ETN provided excellent refractive accuracy and high rates of good distance, intermediate, and near vision. No serious AEs or glistenings occurred.

PURPOSE: This retrospective case series aims to document healthcare providers' (HCP) real-world experience of using the enVista ENVY toric (ETN) intraocular lens (IOL), including satisfaction, IOL utilization patterns, and patient outcomes. This interim sub-analysis reports the patient outcomes.

METHODS: This sub-analysis of a multicenter, cross-sectional, retrospective case series includes case report forms (CRFs) from 11 HCPs from the USA (n=10) and Canada (n=1). HCPs provided ETN electronic medical record cases using a standardized CRF to document real-world clinical performance. Key outcome measures included monocular and binocular vision outcomes (uncorrected distance visual acuity [UDVA], corrected distance visual acuity [CDVA], uncorrected intermediate visual acuity [UIVA], uncorrected near visual acuity [UNVA]), mean refractive spherical equivalent (MRSE), and adverse events (AEs).

RESULTS: Preliminary analysis included 110 pts (168 eyes): 52 unilateral. Mean±SD preop delta K and spherical equivalent target were 1.05±0.53 and -0.04±0.21 (n=167). Monocular vision outcomes were: CDVA of 20/25 or better was achieved in 94% of eyes (n=124); UDVA of 20/32 or better in 83% of eyes (n=151); UIVA of 20/32 or better in 89% of eyes (n=78); UNVA of J2 or better in 66% of eyes (n=118). Mean±SD MRSE and residual cylinder were -0.15±0.42 and -0.46±0.43 (n=111), respectively. No serious adverse events reported.

CONCLUSION: In the cases provided, most patients achieved good distance, intermediate, and near vision, with no reported glistening.

PURPOSE: To evaluate visual outcomes and patient satisfaction in patients who underwent intraocular lens (IOL) exchange surgery with a novel full visual range (FVR) IOL.

METHODS: This retrospective case series included patients dissatisfied with previously implanted IOLs (Clearview 3, Tecnis Odyssey, Alcon PanOptix or a monofocal IOL) who underwent IOL exchange with the enVista Envy FVR IOL. Outcome measures included uncorrected distance and near visual acuity. Subjective patient experience was also assessed following the exchange surgery.

RESULTS: Sixteen eyes of twelve patients underwent IOL exchange with the FVR IOL. Post-exchange, mean logMAR UDVA was 0.09±0.16, with 81.3% of eyes achieving 20/25 or better. Mean logMAR UNVA was -0.08+0.04, with 100% achieving 20/25 or better. Mean MRSE was -0.20±0.32 D. Patients exchanged from ClearView 3 to Envy reported resolution of glare, starbursts, and hazy vision. Patients exchanged from Odyssey noted fewer halos, better contrast, and improved peripheral vision. One eye that exchanged from PanOptix due to constant halos also reported improvement in subjective vision. All patients reported improved satisfaction.

CONCLUSION: Exchange to the enVista Envy FVR IOL provided good distance and near visual outcomes. Symptoms such as glare, starbursts, hazy vision, halos and peripheral vision blur reported with previously implanted IOLs resolved after exchange. Patients expressed high satisfaction with the Envy IOL compared to previously explanted IOLs.

PURPOSE: Low-dose (0.025%) brimonidine tartrate ophthalmic solution (BTOS) effectively treats conjunctival hyperemia, but contains the preservative benzalkonium chloride (BAK). To minimize risk of ocular irritation—important for postsurgical recovery—preservative-free BTOS (BTOS-PF) was developed. This study evaluated the efficacy of BTOS-PF vs BTOS.

METHODS: This multicenter, double-masked, randomized, active-controlled, parallel-group study in healthy adults with ocular redness was conducted at 6 sites in the US. Participants were randomized 1:1 to BTOS-PF or BTOS, which was self-administered 4 times daily ~4 hours apart for 4 weeks. The primary efficacy endpoint was ocular redness score prior to and at 5(+1), 15(+1), 30(+1), 60(+10), 90(+10), 120(+15), 180(+15), and 240(+15) minutes after investigational drug instillation (0–4-unit scale with half-unit increments). As a secondary, supporting efficacy endpoint, participants were also assessed for latency to onset, including measurements at 1 and 5 min post-instillation.

RESULTS: Baseline ocular redness values were comparable between the BTOS-PF (n=190) and BTOS (n=190) groups. Post-instillation redness at all timepoints were comparable between groups and upper confidence limits at all timepoints fell within the predetermined noninferiority limit of 0.22 units. Ocular redness decreased swiftly after instillation with activity seen within 1 minute for both BTOS-PF and BTOS. The mean difference in change from baseline between the BTOS-PF and BTOS groups for Visit 1, minute 1 and Visit 2, minutes 1 and 5 ranged from -0.03 to 0.01 units. indicating maintained activity and statistical non-inferiority between treatment groups.

CONCLUSION: The study met its primary endpoint of statistically noninferiority of BTOS-PF to BTOS in reducing ocular redness. Both BTOS-PF and BTOS demonstrated rapid onset of action—within 1 min— with activity maintained across study visits. BTOS-PF offers patients a means of address postsurgical redness without the risk of BAK-induced irritation.

PURPOSE: Dry eye disease (DED) is common in patients needing cataract surgery and can be further exacerbated in the postoperative period. Perfluorohexyloctane ophthalmic solution (PFHO) is approved for treatment of signs and symptoms of DED. This study evaluated the effects of PFHO treatment before and after cataract surgery in patients with DED.

METHODS: This prospective, multicenter, open-label, phase 4 study (NCT06346340) enrolled patients with DED who were candidates for phacoemulsification with posterior chamber intraocular lens (IOL) implantation. Patients instilled PFHO in both eyes QID for 30 days preoperatively and received a second 30-day PFHO treatment beginning approximately 1 month after surgery. Total corneal fluorescein staining (tCFS), rated on a 0-15 scale; eye dryness, rated on a 100-mm visual analog scale (VAS); Ocular Surface Disease Index (OSDI); root mean square (RMS) higher-order aberrations (HOA) in the central 6.0 mm of the cornea; and visual acuity were assessed before and after each PFHO treatment period.

RESULTS: The study enrolled 97 patients. Mean (SD) tCFS score improved from 5.0 (2.7) to 2.1 (2.2) and 1.3 (1.8) after the first and second 30-day PFHO treatments, respectively (P<0.001 for both. reductions from baseline in eye dryness vas score from 62.3 19.0 to 37.5 23.1 and 25.9 23.3 respectively were observed while osdi score improved from 51.9 16.9 to 30.1 17.6 and 11.9 10.9 p><0.001 for all. most patients experienced stable or improved rms hoas after pfho treatment. the percentage of patients with best-corrected visual acuity bcva of 20 20 or better was 86.0 at the first postsurgical assessment and 91.8 after 30 days of subsequent pfho treatment.>

CONCLUSIONS: Presurgical PFHO treatment resulted in statistically significant reductions in signs and symptoms of DED with further improvement after postoperative treatment, including more patients with BCVA of 20/20 or better. These findings support a role for PFHO in pre-and postoperative management of DED in patients undergoing cataract surgery.

PURPOSE: Dry eye disease (DED) is common in patients undergoing cataract surgery. Perfluorohexyloctane ophthalmic solution (PFHO) forms an anti-evaporative monolayer at the tear-film surface to reduce both signs and symptoms of DED. This study evaluated whether preoperative PFHO treatment affected postoperative refractive accuracy.

METHODS: This prospective, multicenter, open-label, phase 4 study (NCT06346340) enrolled patients with DED who were candidates for phacoemulsification with posterior chamber intraocular lens (IOL) implantation. Patients instilled PFHO in both eyes QID for 30 days preoperatively and received a second 30-day PFHO treatment beginning approximately 1 month after surgery. The 30-day postoperative standard-of-care visit included assessment of refractive outcome (manifest refraction). The primary endpoint was the mean difference between absolute deviations from predicted refractive error in the study eye.

RESULTS: The study enrolled 97 patients (75.3% female; mean age, 68.6 years). The mean difference between absolute deviations in predicted refractive error measured before and after presurgery PFHO treatment was -0.027 ± 0.167 D (P=0.1385). The difference in the baseline predicted refractive error and the predicted refractive error post-PFHO treatment was within 0.3 D for 94.2% of study eyes. The percentage of patients with calculated IOL power within +0.50 D of the correct IOL power was 72.1% before and 83.7% after PFHO treatment. Two adverse events were considered related to treatment (mild eye pruritus and mild noninfective conjunctivitis).

CONCLUSION: In patients with DED undergoing cataract surgery, PFHO did not alter the accuracy of preoperative biometry and keratometry measurements or impact the predicted refractive error. The accuracy of IOL power determination was increased after preoperative PFHO treatment. PFHO was well tolerated in this patient population.

PURPOSE: The ELIOS system (Bausch + Lomb) is the first clinically validated excimer laser trabecular bypass minimally invasive glaucoma surgery (MIGS). This trial evaluated the effectiveness and safety of the MIGS system to reduce intraocular pressure (IOP) in adults with mild-to-moderate primary open-angle glaucoma (POAG) undergoing cataract surgery.

METHODS: This was a prospective, non-randomized 24-month clinical trial at 20 sites in the USA (NCT04899063). Patients were aged ≥45 years with mild-to-moderate POAG, an operable age-related cataract eligible for phacoemulsification with best-corrected visual acuity of 20/40 or worse, medicated IOP of ≤24 mmHg and unmedicated diurnal IOP (DIOP) of 22–34 mmHg. Patients meeting all inclusion criteria underwent the MIGS procedure after uncomplicated cataract surgery. The co-primary effectiveness endpoints were the proportion of patients achieving a decrease in medication-free mean DIOP of ≥20%, and mean change in medication-free DIOP, from baseline at 12 months. Safety was assessed throughout the trial.

RESULTS: A total of 318 patients underwent the procedure (mean±standard deviation [SD] age 70.2±7.4 years). Mean±SD medicated IOP at screening was 17.05±3.01 mmHg and unmedicated DIOP at baseline was 24.53±2.51 mmHg. At Month 12, co-primary effectiveness endpoints were met: 84.2% of patients achieved a ≥20% decrease in unmedicated mean DIOP from baseline (97.5% CI 79.59, 88.84; p=0.0116 vs performance goal of >79%), and mean DIOP change was −8.17 mmHg (97.5% CI −8.65, −7.69; p<0.0001 vs performance goal of 7.2 mmhg. meansd number of medications decreased from 1.50.7 at screening n="318)" to 0.20.7 at month 11 n="298)" with sustained iop reduction throughout follow-up.>

CONCLUSIONS: Both co-primary effectiveness endpoints were met. ELIOS demonstrated clinically meaningful and sustained reduction in unmedicated DIOP in patients with POAG undergoing cataract surgery. Mean IOP reduction of 34.5% at Month 12 aligns with recommended target reduction for mild-to-moderate glaucoma (≥25% reduction to below 17 mmHg).

PURPOSE: This systematic review and meta-analysis aimed to evaluate the long-term efficacy and safety of excimer laser trabeculostomy (ELT) as a standalone procedure or combined with phacoemulsification (Phaco-ELT) in the treatment of patients with glaucoma.

METHODS: ELT is an implant-free, ab-interno, minimally-invasive glaucoma surgery that creates microchannels in the trabecular meshwork, facilitating aqueous outflow while preserving angle anatomy. It can be performed as a standalone procedure or combined with phaco. A systematic literature review was conducted by two independent reviewers using PubMed and EMBASE databases to identify articles that examined efficacy and safety endpoints of ELT or Phaco-ELT procedures in adult patients with glaucoma. Endpoints included absolute reduction in glaucoma medication, intraocular pressure (IOP), and visual acuity at 1 and 2 years follow-up. A total of 14 eligible articles (N=1549 eyes) were identified.

RESULTS: At Year 2, the IOP reduction achieved with ELT and Phaco-ELT was 7.10 mmHg (95%CI:6.25, 7.95; n=105) and 6.72 mmHg (95%CI: 3.01, 10.42; n=130), respectively. Absolute glaucoma medications were reduced by 1.26 (95%CI: 0.74, 1.78; n=95) and 0.58 (95%CI: 0.33, 0.83; n=130), respectively. In patients undergoing phaco-ELT, visual acuity improved by –0.12 LogMAR (95% CI: –0.20, –0.05; n=70). After 1 year, the total complication rate with ELT and Phaco-ELT was 2.67% (95% CI: 1.00, 6.89; n=150) and 4.09% (95% CI: 1.96, 8.34; n=171), respectively, and the rate of additional surgeries was 30.82% (95% CI: 24.14, 38.41; n=159) and 5.55%, respectively.

CONCLUSIONS: This analysis found that ELT reduced IOP and IOP-lowering medication burden in patients with glaucoma, with minimal occurrence of complications and a low rate of secondary interventions. When combined with phaco, ELT results in a simultaneous improvement in visual acuity.

PURPOSE: ELIOS (Bausch + Lomb) is an ophthalmic excimer laser trabecular bypass minimally invasive glaucoma surgery (MIGS) system. This trial assessed the effectiveness and safety of the MIGS system to reduce intraocular pressure (IOP) in adults with primary open-angle glaucoma (POAG) undergoing cataract surgery. Study safety will be focus of this paper.

METHODS: This prospective, non-randomized clinical trial (NCT04899063) enrolled patients aged ≥45 years with mild-to-moderate POAG at 20 sites in the USA. Additional eligibility criteria included operable age-related cataract eligible for phacoemulsification with best-corrected visual acuity (BCVA) ≤ 20/40, medicated IOP of ≤24 mmHg, and unmedicated diurnal IOP of 22–34 mmHg. Patients meeting all eligibility criteria underwent the ELIOS procedure after uncomplicated cataract surgery, with 24-months follow up. Key safety outcomes were the incidence of adverse events (AEs) and endothelial cell density (ECD) loss from baseline, and distribution of postoperative BCVA. Results reflect findings at 12-month.

RESULTS: 318 patients underwent the procedure (mean±SD age 70.2±7.4 years). At 12-mo, 144 ocular AEs were reported in 107 patients (33.6%); 68% occurred within 1-mo, and 32% between Months 1–12. While early postoperative IOP elevations ≥10 mmHg were predominantly transient, the incidence of sustained or later-onset IOP elevation (≥1 month) was low at 1.5%. Most ocular AEs were mild or moderate and occurred in the early postop without clinically meaningful sequelae. ECD loss demonstrated early postoperative reduction with stabilization by Month 3. All patients achieved BCVA of 20/40 or better at 12-mo (n=307). No unanticipated device effects or procedure-related intraoperative AEs occurred.

CONCLUSIONS: Excimer laser trabeculostomy MIGS with ELIOS was associated with a low rate of serious AEs, and over 66% of patients not experiencing any AEs at 12 months. Reported AEs are in-line with those described in the literature for standalone cataract surgery. No intraoperative complications or unanticipated adverse device effects were reported.

PURPOSE: This study aims to demonstrate and quantify corneal incision temperature during phacoemulsification using two platforms operating at different frequencies (28.5 kHz vs 44.5 kHz).

METHODS: Bench: Two phaco needles were tested as part of bench data: B+L 1.8 MICS (A), Alcon Balanced Tip (B). The Needles were operated on Stellaris Elite (28.5 kHz) and Centurion (44.5 kHz) in continuous mode with equal stroke lengths, isolating frequency as a single variable. The Needles were submerged in 2.5 ml BSS and temperature rise was measured with a thermocouple during 5 and 10 second activations. Clinical: Corneal incision temperature was recorded during surgeries on both systems with a Thermal IR camera to record corneal incision temperatures.

RESULTS: TBD

CONCLUSION: TBD

PURPOSE: This prospective, randomized, single-surgeon study evaluated the safety and efficacy outcomes of transepithelial photoreactive keratectomy (tPRK) compared with conventional photoreactive keratectomy (PRK) at 3 years of follow-up.

METHODS: Thirty-five patients who underwent refractive surgery for correction of ametropia were evaluated. Patients were bilaterally treated with PRK in one eye and tPRK in the other. Clinical endpoints include absolute refractive predictability, adverse events (AEs), manifest refraction spherical equivalent (MRSE), monocular uncorrected and corrected distance visual acuity (UDVA/CDVA) and patient-reported visual outcomes at 36 months.

RESULTS: Both treatment approaches achieved excellent efficacy and safety with no statistically significant differences between study groups. Median photopic UDVA was 0.0 logMAR (range -0.20 to +0.50) and median photopic CDVA -0.10 logMAR (range -0.20 to 0.00); median mesopic UDVA was 0.0 logMAR (range -0.10 to -0.50) and mesopic CDVA -0.10 logMAR (range -0.10 to -0.40). Median MRSE was close to plano in both arms (range -0.50 D to +0.50 D). Contrast sensitivity remained comparable under both photopic and mesopic conditions. Intraocular pressure was comparable and unremarkable, and no haze or adverse events were reported.

CONCLUSION: The tPRK procedure offers the surgeon improved speed and efficiency over conventional PRK. In this analysis, tPRK provided outcomes equivalent to conventional PRK in terms of refractive predictability, visual acuity, and contrast sensitivity. Both procedures were well tolerated, effective, and stable through 36 months.

PURPOSE: This retrospective case series study aimed to document eyecare practitioners' (ECPs') real-world experience using Vyzulta (latanoprostene bunod; LB), including satisfaction, utilization patterns, and patient (pt) outcomes. This interim sub-analysis reports ECP satisfaction and utilization patterns.

METHODS: This sub-analysis of a retrospective, multicenter, cross-sectional study includes survey responses from ≥30 ECPs from Brazil, Canada, Hong Kong, Mexico, South Africa, South Korea, Taiwan, Thailand, Tunisia, Turkey, Ukraine, the UAE, and the USA. ECPs were currently licensed optometrists or ophthalmologists with ≥3 years' experience treating pts, and who had prescribed LB on-label (reduction of intraocular pressure in pts with open-angle glaucoma or ocular hypertension) to ≥10 pts in the last 12 months. ECPs completed a retrospective user-experience survey about their experience with LB. Key outcomes included clinical practice setting, LB utilization patterns, and ECP satisfaction with LB.

RESULTS: TBD – To be updated by February 2026

CONCLUSIONS: TBD – To be updated by February 2026

PURPOSE: Despite its high prevalence, dry eye and dry eye disease (DED) are often misunderstood, undertreated, and their impacts underestimated. To optimize surgical outcomes, minimizing DED signs and symptoms is key. This online survey sought to understand the prevalence, perceptions, and impact of DED in US adults.

METHODS: US adults, including DED sufferers (those who often/always experience eye dryness and/or have been diagnosed by a healthcare professional) completed an online survey administered by The Harris Poll. Harris online poll sampling precision is measured using a Bayesian credible interval. Here, the sample data are accurate to within ±3.0 with a 95% confidence interval (CI), with statistically significant differences between the DED sufferers and non-sufferers at the 95% CI. This credible interval was wider among population subsets analyzed. 2003 adults were recruited, including 461 self-identified dry eye sufferers.

RESULTS: Among non-sufferers, 74% reported related symptoms (tired eyes, light sensitivity, redness) but only 15% associated these symptoms with dry eye. 70% said they did not know much about preventing or treating dry eye and 44% did not know untreated dry eye can lead to other problems including vision loss. Among dry eye sufferers, 33% had never visited an ECP for dry eye and 52% of sufferers simply tolerated symptoms despite 81% being constantly aware of their eyes and 67% reducing/stopping activities like screen time and reading. For those sufferers who did see an ECP about their dry eye, 67% waiting for more than 6 months to do do (31% over 2 years).

CONCLUSION: Dry eye remains largely undertreated, causing daily discomfort and permitting potential worsening. US ECPs have an opportunity to better engage and educate their patients to help address this. For the ocular surgeon, ensuring patients recognize how to mitigate the effects of dry eye may improve pre- and post-surgery ocular health.

PURPOSE: Lifitegrast ophthalmic solution, 5.0% is an anti-inflammatory agent indicated for the treatment of signs and symptoms of dry eye disease. This post hoc analysis of phase 3 pivotal data identified patients with rapid and pronounced reduction in dry eye symptoms with lifitegrast treatment and evaluated defining characteristics.

METHODS: This was an exploratory analysis of data from the OPUS-2 and OPUS-3 studies (NCT01743729, NCT02284516): 12-week, prospective, double-masked, multicenter, placebo-controlled, randomized, parallel-arm clinical trials. Pooled data in the lifitegrast treatment arm were analyzed using a cluster analysis to identify homogenous populations of patient response types based on percent change from baseline in eye dryness score (EDS; as evaluated on a VAS 0-100 scale) at Days 14, 42, and 84. Patients with Sjögren's syndrome or incomplete data were excluded from the analysis. Patient demographics and baseline characteristics among the defined subgroups were evaluated.

RESULTS: Five patient subgroups were identified in the lifitegrast treatment arm: early sustained responders with ≥60% EDS reduction at all time points (n=113; 17.7%); steady responders with ≥20%, ≥40%, and ≥60% reduction at Days 14, 42, and 85 (n=113; 17.7%); Day 84 response of ≥60% (n=127; 19.9%); Day 84 response of ≤30% to <60% n="119;" 18.7 day 84 response of><30% n="166;" 26.0. there were significant differences in mean symptom scores across the 5 patient subgroups p><0.001), with numerically lower mean symptom scores for eye pain burning stinging foreign body sensation and photophobia in the patients demonstrating an early sustained response.>

CONCLUSION: The majority of patients treated with lifitegrast had ≥60% reduction in EDS by Day 84. The group with rapid and sustained EDS reductions by week 2 tended to have lower symptom scores than the other subgroups, suggesting that early treatment may be beneficial for maximal response. Further studies to corroborate these findings are warranted.

PURPOSE: To document patient characteristics, diagnostic tests, and treatment of dry eye disease (DED) in patients outside of the clinical trial setting, leveraging real-world evidence (RWE).

METHODS: Retrospective cohort study using the American Academy of Ophthalmology IRIS® (Intelligent Research in Sight) Registry linked to pharmacy claims data. Patients were diagnosed with DED and initiated an index lifitegrast DED prescription therapy between Jan 1, 2017, and Dec 31, 2024.

RESULTS: Study included 143,005 patients who initiated lifitegrast DED therapy (mean age, 61 y; 80% female). Ocular comorbidities included cataracts (41%), glaucoma (9%), and age-related macular degeneration (5%). Non-ocular included hyperlipidemia (45%), hypertension (43%), diabetes (21%), obstructive sleep apnea (11%), chronic obstructive pulmonary disease (6%) rheumatoid arthritis (6%) and Sjögren's syndrome (6%). About 7% of eyes (n=19,654) had recorded tear film break-up time measurements, 2% (n=4877) had Schirmer's, and 11% (n=29,830) had tear osmolarity tests. Prior to index therapy, 11% of patients had received a prescription (predominantly topical cyclosporine 0.05%); 8% punctal plugs.

CONCLUSION: This large RWE study shows that patients with DED often have significant ocular and systemic comorbidities. Diagnostic testing remains underutilized, highlighting practice gaps and informing future strategies to improve diagnosis and treatment.

PURPOSE: Lifitegrast ophthalmic solution 5% is indicated for treatment of signs and symptoms of dry eye disease (DED). Lifitegrast demonstrated symptom relief starting at 2 weeks and a favorable safety profile in clinical trials. We report findings from 2 real-world evidence studies, a provider survey and a pharmacovigilance (PV) database analysis.

METHODS: Eyecare providers (ECPs: ophthalmologists and optometrists) completed a survey and submitted case reports on patients treated with lifitegrast. Twelve ECPs treated an average of 1288 patients with DED annually, with 21% of these patients, on average, receiving lifitegrast. Seven ECPs provided 36 case reports of patients (mean age, 51 years; mean number of follow-up visits, 5) with aqueous-deficient (39%), evaporative (14%), or mixed (47%) DED. Postmarketing safety data from approval in the United States (July 2016) to July 10, 2024, were reviewed using a company PV database with reports from providers and patients.

RESULTS: In the survey, two-thirds (67%) of ECPs reported near/complete symptom resolution in patients after 1-3 months of lifitegrast treatment. Case report data indicated that improvement was sustained throughout treatment, with a mean duration of 29 months (range, 1-69). Adverse events (AEs) considered by the ECPs as related to lifitegrast use included blurred vision, burning/stinging, and dysgeusia; all were mild or moderate in severity. In the postmarketing database, cumulative patient exposure with 8 years of worldwide use was estimated at 915,260 patient treatment-years. No new safety signals were identified.

CONCLUSION: Results from the ECP survey show that treatment with lifitegrast provides sustained symptom relief in patients with DED, and the AEs reported were consistent with the known safety profile of lifitegrast. Long-term use revealed no new or changing safety signals during routine safety monitoring.

PURPOSE: To assess the treatment of dry eye disease (DED) with lifitegrast and clinical outcomes using real world evidence.

METHODS: Retrospective observational analysis of American Academy of Ophthalmology IRIS® (Intelligent Research in Sight) Registry electronic health records data that were linked to pharmacy claim information. Adults with a prior diagnosis of DED were indexed on first pharmacy claim for lifitegrast from Jan 1, 2017, through Sept 30, 2023 (index period). Additional criteria included ≥1 year pre-index and ≥1-year post-index pharmacy claims coverage. Endpoints analyzed will include changes from pre-index in tear film break-up time (TFBUT) and visual acuity over the study period. Results will also include study population stratifications by change in TFBUT (eg, improved; stable; improved/stable).

RESULTS: TBD

CONCLUSION: TBD